IL2 and colitis: In light of our observations that IL-2/JES6-1 immunocomplexes induce Foxp3+ Tregs, but also IL-5-producing ILC2s and activated eosinophils during DSS-induced colitis, we next attempted a combined approach to optimally ameliorate colitis by expanding colonic Foxp3+ Tregs via delivery of IL-2/JES6-1 immunocomplexes while simultaneously blocking eosinophil accumulation and activation by using anti-IL-5 monoclonal antibodies (mAb).